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Dear Editor,
Thrombocytopenia is a common complication seen in patients
with chronic liver disease, precluding or interfering invasive diag-
nostic and therapeutic procedures. Etiology is multifactorial,
including hypersplenism, bone marrow suppression by HCV and
a possible reduction in the level or activity of the hematopoietic
growth factor thrombopoietin (TPO)(1). In addition to thrombo-
cytopenia, functional platelet defects has been suggested. Romi-
plostim (Nplate®, Amgen Inc, Thousands Oaks, Calif) is a new
thrombopoietin receptor agonist indicated for the treatment of
thrombocytopenia in patients with chronic immune thrombocy-
topenic purpura who have had an insufficient response to corti-
costeroids, immunoglobulin or splenectomy (2). It has been not
tested in chronic liver disease until now. Another thrombopoietin
receptor agonist, eltrombopag (3), has been tested in chronic liver
disease undergoing an elective invasive procedure. Although
results were satisfactory in terms of platetelet count and avoidance
of platelet transfusions, the trial was early stopped due to the
observed incidence of portal vein thrombosis in the study group
(4). We report a case of a Jehovah’s Witness that could success-
fully managed with romiplostim use.
Case report
A 62-years-old male with liver cirrhosis secondary to HCV
was diagnosed of a 30 mm hepatocellular carcinoma in segment
IVB in contact with left portal vein by two radiological tests.
The patient was Child A with 30 x 109 platelets/L. A trans-arte-
rial chemo-embolization procedure was planned to treat his
tumor. After two procedures a complete necrosis was not
achieved and viable tumor was showed by CT. After informed
consent, romiplostim therapy was begun as compasive use, treat-
ing to improve the platelet count to perform a radiofrequency
ablation. The romiplostim dose was weekly varied depending
on the platelet count. We planned the procedure after three doses
of romiplostim but it was delayed because the increase on
platelet count was insufficient to safely perform the procedure.
The dose of romiplostim subcutaneous weekly use and the
Fig. 1. Dose of romiplostim subcutaneously injected weekly and platelet
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platelet count evolution are shown in figure 1. After 10 weeks
of therapy a percutaneous ethanol injection (PEI) with a single-
shot technique was performed. Immediately after the procedure
an ultrasound with contrast showed no vascularization of the
nodule and a partial thrombosis of the left portal vein in contact
with the tumor. Anticoagulation with tinzaparine was begun.
At four weeks after PEI, a new CT showed permeability of portal
veins and a complete necrosis of the nodule without hypervas-
cularization. 
There are some concerns about romiplostim use: worsening
thrombocytopenia after drug discontinuation and thrombotic
events related to an elevated number of platelets.
In our patient, platelet count decreased slowly to previous fig-
ures after discontinuation of therapy. A partial thrombosis of the
portal vein in contact with the treated area appeared during the
procedure but disappeared after 4 weeks of anticoagulant therapy
with a low-molecular weight heparin. We think it was probably
related to an unnoticed injection of ethanol in the portal vein and
not related to romiprostim use. Useful and safe thrombopoietin
receptor agonists are needed in different clinical situations for
chronic liver disease patient management; in our case we could
successfully treat this patient, Jehovah’s witness, who rejected
platelet transfusion. Well designed clinical trials with romiplostim
are required to study its use in this setting.
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